In a drive to become the leading middle market corporate and investment bank, KeyCorp said it acquired Pacific Crest Securities.
Pacific Crest Securities, which is a technology-focused investment bank and capital markets firm, will become part of KeyBanc Capital Markets. The transaction is expected to close in the third quarter if regulators approve the deal.
Pacific Crest Securities, based in Portland, Oregon, employs 170 and has expertise in internet and digital media, software and systems, communications, semiconductors, and clean technology. – Abby Latour
This is S&P Capital IQ’s monthly loan market update. In this post, we concentrate on the trends at work in the European leveraged loan market during 2014 so far, including an increase in M&A financing and some signs of heating in the market. We’ll also touch on the question of whether some slowdown is to be expected.
Out of the €45 billion of leveraged loan issuance so far this year, M&A-related deals contributed €25 billion, more than double what was raised in the first half of last year. This total was boosted by some jumbo corporate M&A deals, most recently the cross-border financing for Jacobs Douwe Egberts. Among sponsor-backed buyouts, LCD tracked an increase in the number of asset sales by corporates and families, bringing some welcome debut borrowers to the loan market.
Institutional investors continued to show strong appetite for leveraged loans during the second-quarter, and heavy repayments on existing loans spurred them on. In fact repayments reached a record quarterly high of €16.6 billion, based on the S&P European Leveraged Loan Index, as the chart shows.
Adding to institutional demand, there was lively issuance of new-generation CLOs, particularly during June, including some new managers entering the 2.0 market, and sources say the pipeline for further CLO issuance in the second half of the year looks healthy.
Through much of the year so far, there has been relatively little complaint from buyside firms about leverage multiples, and indeed first-lien leverage is pretty much flat on last year at around 3.7 times EBITDA. But second-lien tranches are appearing more frequently, and this helped drive total leverage a little higher, to 4.9x. Some arrangers argue leverage is unlikely to spiral up and up because this would result in deals coming to market with low single-B ratings, these often being hard to shift in syndication.
Instead, the market is showing its aggression in other ways – particularly in the use of covenant-lite loans. €10 billion of cov-lite paper – a record – has been raised this year, meaning that roughly one in three euros sold to fund managers had no maintenance covenants. The ELLI Index now includes a 13% cov-lite portion, the highest in its history – although a long long way behind the U.S., where the trend started.
However, from the point of view of yields, Europe looks less aggressive than it did earlier in the year as this chart suggests. Behind the scenes, yields on domestic European deals were flat from the first quarter to the second. But in line with the weaker technical picture in the U.S. market, cross-border yields widened in recent months, dragging the average out too.
Looking ahead, some kind of summer slowdown is likely, but arrangers say they are pitching on some aggressively structured deals and will be looking out for signs of pushback among investors if terms get too heated.
Sprint has obtained commitments from several banks providing a roughly $20 billion bridge loan to back the company’s effort to acquire T-Mobile, sources said. The banks will launch the deal soon, sources added.
Earlier this week, reports emerged regarding Sprint’s interest to purchase rival wireless provider T-Mobile in a deal that would total $32 billion. SoftBank, which completed its roughly $21.6 billion acquisition of Sprint in July 2013, would hold a controlling interest in the combined company.
S&P earlier this week disclosed that Sprint’s rating would likely be no higher than BB- after the merger and that SoftBank’s ratings would be lowered to BB, from BB+. S&P expects SoftBank’s consolidated debt to EBITDA – consolidating Sprint and T-Mobile, and including the acquisition and spectrum auction cash requirements – would be around mid-5x or higher in fiscal year 2014 annualized, which is above the current 5x threshold for SoftBank’s current rating. Sprint is currently rated BB-/Ba3.
Regulatory hurdles, though, could be an issue for Sprint. In a report earlier this week, S&P said that the combination of Sprint and T-Mobile would face intense regulatory scrutiny and wouldn’t be approved by the FCC and Department of Justice. In 2011, the FCC rejected AT&T’s $39 billion bid to acquire T-Mobile, suggesting that it wanted to maintain four nationwide wireless carriers. Sprint’s acquisition of T-Mobile would leave the U.S. with three national carriers. – Richard Kellerhals
Accounts this morning received allocations of the $2.175 billion B term loan for Ortho-Clinical Diagnostics, which advanced to 100.375/100.875 after breaking for trading at 99.25/100.25, from issuance at 99, according to sources. The seven-year loan is priced at L+375, with a 1% LIBOR floor. Proceeds from loan, along with a $1.3 billion issue of 6.625% notes due 2022, will be used to fund The Carlyle Group’s purchase of the laboratory instruments and diagnostic products business from Johnson & Johnson. Barclays, Goldman Sachs, Credit Suisse, UBS, and Nomura arranged the loan. The loan cleared wide of original talk, among other investor-friendly changes, though the adjoining bond deal was upsized by $150 million to reduce the sponsor’s equity check by a like amount. A $350 million, five-year revolving credit rounds out the financing. Terms:
$2.175 billion B term loan
12 months 101 soft call
S&P recovery rating
Barc, GS, CS, UBS, Nom
Ticking fee of 375 bps payable 31 days after allocations
Accounts this afternoon received allocations of the covenant-lite $4.6 billion B term loan for Avago Technologies, which broke for trading at 100/100.5, from issuance at 99.5, according to sources. The seven-year loan is priced at L+300, with a 0.75% LIBOR floor. Deutsche Bank, Barclays, Bank of America Merrill Lynch, and Citigroup arranged the loan, which cleared tight to original talk. The publicly traded semiconductor manufacturer will use proceeds to support its $6.6 billion acquisition of LSI Corp. The senior secured financing also includes a $500 million revolver, while Avago is also planning to fund the deal with a $1 billion investment from Silver Lake Partners, which would be in the form of a seven-year 2% convertible note, with a conversion price of $48.04 per share or preferred stock. The company will also use $1 billion of cash from the combined balance sheet to fund the transaction. Terms:
$4.6 billion B term loan
Fund acquisition of LSI
YTM (once funded)
12 months 101 soft call
S&P recovery rating
DB, Barc, BAML, Citi
Ticking fee of 150 bps kicks in on June 1, stepping to 300 bps July 1; includes a 24-month MFN sunset provision
The $1.1 billion covenant-lite term loan for Men’s Wearhouse ticked to 99.625/100.125 after breaking secondary late this afternoon at 99.5/100, from issuance at 99, according to sources. The seven-year loan is priced at L+350, with a 1% LIBOR floor. J.P. Morgan and Bank of America Merrill Lynch arranged the deal, which cleared at the tight end of talk. Proceeds back the publicly traded retailer’s planned $1.8 billion acquisition of Jos. A. Bank. Since the deal isn’t expected to close until the third quarter, lenders will be paid a ticking fee of half of the drawn spread beginning in June; the fee steps up to the full drawn spread in July. The issuer is also putting in place a $500 million, five-year asset-based revolver. The financing for the merger is also expected to include a $600 million issue of unsecured notes, which have been bridged, SEC filings show. BAML is expected to be left lead on the bond deal. Terms:
A Deutsche Bank-led arranger group this morning cut pricing on Avago Technologies‘ $4.6 billion M&A term loan to L+300, with a 0.75% LIBOR floor, at 99.5, sources said. The 101 soft call premium has been extended to 12 months from six months, sources said.
Investors earlier oversubscribed the loan line with talk of L+325, with a 0.75% LIBOR floor and a 99 offer price, according to sources. As revised, the loan will yield 3.89% to maturity, down from 4.24% at initial guidance.
Recommitments are due by close of business today. Allocations are expected on Wednesday.
Additional changes include a ticking fee that kicks in at 150 bps on June 1, rising to 300 bps on July 1. MFN has been added with a 24 month sunset, and a Luxco borrower has been added to what was previously a Cayman Islands borrower, sources explained.
The seven-year B term loan is part of the financing for Avago’s $6.6 billion acquisition of LSI Corp. The financing also includes a $500 million, five-year revolver.
Issuer ratings have firmed at BB+/Ba2/BB+, and the term loan is rated BBB-/Ba1/BBB-, with a 2 recovery rating from Standard & Poor’s. The loan is being arranged by Deutsche Bank, Barclays, Bank of America Merrill Lynch, and Citigroup.
As reported, Avago is also planning to fund the deal with a $1 billion investment from Silver Lake Partners, which would be in the form of a seven-year 2% convertible note with a conversion price of $48.04 per share or preferred stock. Deutsche Bank is acting as lead manager. Avago also intends to put $1 billion of cash into the transaction.
Avago is acquiring LSI for $11.15 per share. Including the SLP note, gross debt/LTM EBITDA is 3.8x.
Ian Gilday is expected to start a new role this summer at Morgan Stanley as co-head of European leveraged and acquisition finance, alongside Matt Naber, according to market sources. Gilday brings 12 years’ experience in risk management, team building, and origination across the leveraged finance markets.
The hire further builds Morgan Stanley’s leveraged financing platform, and follows the hire of Yannick Perreve last year to spearhead the bank’s leveraged finance sponsor business in Europe. Emanuela Cisini also joined the leveraged finance team last July as executive director, while Richard Stiens was promoted to managing director within the team.
LCD reported earlier this week that Gilday had left his previous role at Goldman Sachs, having spent nine years at the bank. Most recently, Ian worked as head of EMEA CLO origination for the bank, a role he started last June, and prior to that he was head of syndicate and leveraged capital markets for the EMEA region. Before joining Goldman, Gilday spent five years in Merrill Lynch’s European leveraged finance team. –Sarah Husband
Credit Suisse is providing financing for Thoma Bravo’s $930 million purchase of TravelClick from middle-market private equity firm Genstar Capital Management, sources said.
The sale is expected to close in the second quarter. Evercore served as financial advisor to Genstar and TravelClick.
TravelClick, based in New York City, provides reservations technology systems and marketing services for hotels.
Genstar and Bain Capital Ventures acquired TravelClick in 2007. Since the acquisition, TravelClick’s revenue and EBITDA have more than doubled, according to a joint press release from Genstar and Bain.
In March 2011, BMO Capital Markets arranged a $160 million term loan (L+500, 1.5% LIBOR floor) and a $20 million revolver to refinance junior and senior debt at TravelClick.
Last year, BMO arranged a $90 million second-lien term loan due 2018 for TravelClick to pay a dividend. At the same time, $192 million of TravelClick’s first-lien debt was repriced to L+450, with a 1.25% LIBOR floor.
To finance the 2007 buyout, San Francisco-based Genstar lined up a $105 million senior secured loan via Jefferies and $40 million of mezzanine debt via Blackstone Group. – Abby Latour
The $1.3 billion B term loan backing Mallinckrodt International Finance’s acquisition of Cadence Pharmaceuticals broke for trading today at 100/100.5, from issuance at 99.75, according to sources. The seven-year loan is priced at L+275, with a 0.75% LIBOR floor. Deutsche Bank arranged the loan, which cleared inside of original talk. The Dublin-based pharmaceutical concern is acquiring publicly held Cadence for $14 per share, or $1.3 billion. Terms: